This article is a correction to:
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
Chilam Chan1
Marta Lustig2
Niklas Baumann2
Thomas Valerius2
Geert van Tetering1†
Jeanette H. W. Leusen1*†- 1Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
- 2Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
A Corrigendum on
Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) 13:932155. doi: 10.3389/fimmu.2022.932155
In the published article, there was an error in Figure 5 as published. The mitochondrion was misplaced in this figure. The corrected Figure 5 and its caption appear below
FIGURE 5
Figure 5 Strategies for inhibiting myeloid checkpoints. 1) Genetic knock out of target genes involved in the inhibitory pathway. 2) Specific blocking of target checkpoint molecules with mAbs or soluble ligand-Fc fusion proteins to inhibit receptor binding and checkpoint axis activation. 3) Bispecific antibodies that target both TAA and checkpoint molecules simultaneously to avoid off-target side effects.4) Biologics that alter the structure of the target protein, preventing it from binding to the receptor, or that inhibit expression or block the target protein.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: IgA, myeloid checkpoints, neutrophils (PMNs), cancer immonotherapy, immune checkpoint, antibodies, CD47-SIRPalpha axis, macrophages
Citation: Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? Front. Immunol. 13:1017924. doi: 10.3389/fimmu.2022.1017924
Received: 12 August 2022; Accepted: 22 August 2022;
Published: 13 September 2022.
Edited and Reviewed by:
Peter Boross, Genmab, NetherlandsCopyright © 2022 Chan, Lustig, Baumann, Valerius, van Tetering and Leusen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jeanette H. W. Leusen, jleusen@umcutrecht.nl
†These authors have contributed equally to this work